Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Surrozen, Inc./DE

Ticker
SRZN
Sector
Industry
Report date
November 10, 2026
Valye AI Score

70

High visibility
Recent developments
Recent developments summary

Recent developments highlight Surrozen's clinical progress, regulatory milestones, financing activities, and analyst coverage.

Recent developments:
  • Surrozen reported third quarter 2026 financial results and announced plans to expand its DUET clinical study to 150 patients, indicating ongoing clinical development efforts [N1].
  • The FDA cleared Surrozen's IND application for SZN-8141 in diabetic macular edema, marking a key regulatory milestone [N2].
  • Surrozen submitted the IND application for SZN-8141 in diabetic macular edema earlier in 2026, progressing its clinical pipeline [N3].
  • The company highlighted its Wnt retina pipeline and IND timeline at an H.C. Wainwright event, emphasizing its focus on ophthalmology therapies [N4].
  • Surrozen secured $175 million in an oversubscribed private placement to advance its ophthalmology pipeline and discontinued development of SZN-043 to prioritize resources [N5].
  • Multiple analyst firms including HC Wainwright, TD Cowen, and Cantor Fitzgerald initiated coverage with buy or overweight recommendations, reflecting external interest [N8][N5].
Overview

Surrozen, Inc./DE operates as a clinical-stage biopharmaceutical company specializing in developing therapies targeting retinal diseases through modulation of the Wnt signaling pathway. Its lead candidate, SZN-8141, is in clinical development for diabetic macular edema, having received FDA IND clearance. The company focuses on advancing its ophthalmology pipeline through clinical trials such as the DUET study, which is planned to expand to 150 patients. Surrozen has raised significant capital to fund its development programs and has discontinued non-core assets to prioritize its pipeline. The company currently generates no revenue and reports net losses typical of clinical-stage biopharma firms.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Surrozen, Inc./DE is a clinical-stage biopharmaceutical company focused on ophthalmology therapies, particularly retinal diseases. The company is advancing its Wnt pathway retina pipeline, including SZN-8141, which has received FDA IND clearance for diabetic macular edema. Surrozen plans to expand its DUET clinical study to 150 patients and has secured $175 million in financing to support its pipeline. As of September 30, 2026, the company reported strong liquidity with $100.4 million in cash and equivalents and a current ratio of 7.56, alongside a net loss consistent with clinical-stage operations [S2][N1][N2][N3][N5].

Scenarios for SRZN

Bull case model:

Surrozen's focused ophthalmology pipeline, particularly the advancement of SZN-8141 with FDA IND clearance and planned expansion of clinical studies, demonstrates progress in clinical development. The company's ability to secure substantial financing supports ongoing research and development activities. Positive analyst coverage and external validation through multiple buy and overweight recommendations reflect market interest. If clinical trials yield favorable results, Surrozen's proprietary Wnt pathway therapies could address unmet needs in retinal diseases.

Bear case model:

Surrozen operates without current product revenues and reports significant net losses, reflecting the high-risk nature of clinical-stage biopharmaceutical development. The success of its pipeline depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain. Discontinuation of certain development programs indicates challenges in pipeline prioritization. The company faces competition from other firms developing ophthalmology therapies and must manage capital requirements to sustain operations. Insider sales may raise questions about management confidence.

Moat:

Surrozen's moat is primarily based on its proprietary Wnt pathway technology platform targeting retinal diseases, which is a specialized and complex area of drug development. The company's focus on ophthalmology and its lead candidate's regulatory progress provide potential differentiation. However, as a clinical-stage company without approved products or revenues, its competitive advantage depends on successful clinical development and regulatory approvals, which remain uncertain and subject to risks inherent in biopharmaceutical innovation.

Risks overview
Risks summary
The primary risk for Surrozen is the uncertainty inherent in clinical-stage biopharmaceutical development, including clinical trial outcomes, regulatory approvals, and financial sustainability.
Risks details:

• Clinical Development Risk: Surrozen's lead candidates are in early clinical stages, and failure to demonstrate safety or efficacy could materially impact the company's prospects.
• Regulatory Risk: Obtaining and maintaining regulatory approvals such as IND clearance is critical; delays or denials could hinder development timelines.
• Financial Risk: The company currently has no product revenues and depends on financing to fund operations; inability to raise capital could affect development activities.
• Competitive Risk: Surrozen faces competition from other companies developing therapies for retinal diseases, which may impact market opportunities.

FINAL FORECAST FOR SRZN

Final take one line
Surrozen exhibits very high visibility through detailed clinical development progress, regulatory milestones, and strong liquidity as a clinical-stage ophthalmology-focused biopharma.
Final take 12 to 24 month view

Business trends: Continued clinical development of SZN-8141 and expansion of DUET study, supported by regulatory IND clearance and focused pipeline prioritization.
Execution milestones: Advancement of clinical trials, FDA regulatory progress, and capital raising through private placements.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, financial sustainability, and competitive pressures in ophthalmology therapeutics.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

70
LLM visibility overview
LLM Visibility known facts
  • Surrozen, Inc./DE is a clinical-stage biopharmaceutical company focused on developing therapies in ophthalmology, particularly targeting retinal diseases.
  • The company is advancing its Wnt pathway-based retina pipeline, including the drug candidate SZN-8141.
  • Surrozen submitted an IND application for SZN-8141 in diabetic macular edema and received FDA clearance for this IND, indicating regulatory progress for this candidate [N3][N2].
  • Surrozen plans to expand its DUET clinical study to 150 patients, reflecting ongoing clinical development efforts [N1].
  • The company has prioritized its ophthalmology pipeline and discontinued development of SZN-043, indicating a strategic focus on select assets [N5].
  • Surrozen secured $175 million in an oversubscribed private placement to advance its ophthalmology pipeline, demonstrating capital raising success [N5].
  • Multiple analyst firms including HC Wainwright, TD Cowen, and Cantor Fitzgerald have initiated coverage with buy or overweight recommendations, indicating external interest and coverage [N8][N5].
  • As of September 30, 2026, Surrozen reported cash and cash equivalents of approximately $100.4 million and current assets of about $102.9 million, with current liabilities of $13.6 million, resulting in a strong current ratio of 7.56 and cash ratio of 7.37, reflecting solid liquidity [S2].
  • The company reported zero revenue and a net loss of approximately $129.7 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$11.02, consistent with a clinical-stage biopharma profile [S2].
  • Surrozen's business model is centered on clinical development and regulatory advancement of novel ophthalmology therapies, with no current product revenues.
  • Recent insider sales by executives were reported in early 2025, which is a typical disclosure for public companies [N5].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-23 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Surrozen, Inc. Reports Third Quarter 2026 Financial Results and Plans to Expand DUET Study to 150 Patients | https://www.nasdaq.com/articles/surrozen-inc-reports-third-quarter-2026-financial-results-and-plans-expand-duet-study-150
  • N2 | 2026-10-02 | www.nasdaq.com | Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema | https://www.nasdaq.com/articles/surrozens-szn-8141-ind-cleared-fda-diabetic-macular-edema
  • N3 | 2026-09-08 | www.nasdaq.com | Surrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema | https://www.nasdaq.com/articles/surrozen-submits-ind-application-szn-8141-diabetic-macular-edema
  • N4 | 2026-07-22 | www.nasdaq.com | Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright | https://www.nasdaq.com/articles/surrozen-highlights-wnt-retina-pipeline-szn-8141-ind-timeline-hc-wainwright
  • N5 | 2026-04-22 | www.nasdaq.com | TD Cowen Initiates Coverage of Surrozen (SRZN) with Buy Recommendation | https://www.nasdaq.com/articles/td-cowen-initiates-coverage-surrozen-srzn-buy-recommendation
  • N6 | 2026-04-15 | www.nasdaq.com | Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock? | https://www.nasdaq.com/articles/avita-medical-rcel-soars-141-further-upside-left-stock
  • N7 | 2026-04-14 | www.nasdaq.com | Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? | https://www.nasdaq.com/articles/surrozen-srzn-surges-59-indication-further-gains
  • N8 | 2026-02-19 | www.nasdaq.com | Cantor Fitzgerald Initiates Coverage of Surrozen (SRZN) with Overweight Recommendation | https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-surrozen-srzn-overweight-recommendation
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine